Last reviewed · How we verify
elemental iron (NovaFerrum®)
Elemental iron replaces depleted iron stores and serves as a cofactor for hemoglobin synthesis, restoring oxygen-carrying capacity in iron-deficient patients.
Elemental iron replaces depleted iron stores and serves as a cofactor for hemoglobin synthesis, restoring oxygen-carrying capacity in iron-deficient patients. Used for Iron deficiency anemia, Iron supplementation in infants and children.
At a glance
| Generic name | elemental iron (NovaFerrum®) |
|---|---|
| Also known as | Generic Name: polysaccharide iron vitamin mineral complex |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Iron supplement |
| Target | Iron (Fe2+/Fe3+) — cofactor for hemoglobin and myoglobin synthesis |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Iron is an essential mineral required for the formation of hemoglobin and myoglobin, proteins that transport and store oxygen in red blood cells and muscle tissue. NovaFerrum® is a liquid formulation of elemental iron designed for oral supplementation in patients with iron deficiency anemia. By replenishing iron stores, the drug enables normal erythropoiesis and reverses the symptoms and complications of iron deficiency.
Approved indications
- Iron deficiency anemia
- Iron supplementation in infants and children
Common side effects
- Gastrointestinal upset (nausea, constipation, abdominal discomfort)
- Dark stools
- Metallic taste
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: